Research on long COVID in children is limited, and reported prevalences range widely, from less than 1% to 70%. And while it's a relatively new condition in an evolving field, experts say it could be better defined and measured through well-designed longitudinal studies that take children's unique presentations into account.
...in JAMA Network Open, an observational Canadian study ties the antiviral drug combo nirmatrelvir-ritonavir (Paxlovid) to a lower risk of hospitalization or death only in very high-risk COVID-19 patients with weakened immune systems.
...in JAMA Network Open, researchers provide new evidence that the prevalence of SARS-CoV-2–associated sepsis among hospitalized adults is higher than previously thought, but deaths from the condition became less frequent as the pandemic progressed.
...experts on the front lines and doing data analysis say it’s too soon to declare that Covid has achieved seasonality. Looking back over the previous three years, they do see patterns: a spike at some point in the summer, such as the arrival of the Delta variant in 2021, and a spike sometime in the late fall or winter, such as the Thanksgiving surge of Omicron later that year. But those spikes haven’t occurred at the exact same time from year to year, and it’s possible they didn’t all arise for the same reasons.
